Mylan/Watson Emsam Label Discussions Await Marketing Partner
This article was originally published in The Pink Sheet Daily
Executive Summary
The joint venture Somerset is looking to sign a commercialization agreement with a company that has significant experience in the psychiatric market. The company would participate in labeling discussions for Emsam which is "approvable" at FDA.